{"id":"https://openalex.org/W4297965543","doi":"https://doi.org/10.1080/14737167.2022.2130761","title":"Cost-effectiveness evaluation of mirabegron versus anti-muscarinics and third-line therapies: a systematic review","display_name":"Cost-effectiveness evaluation of mirabegron versus anti-muscarinics and third-line therapies: a systematic review","alternate_titles":[],"publication_year":2022,"publication_date":"2022-09-29","ids":{"openalex":"https://openalex.org/W4297965543","doi":"https://doi.org/10.1080/14737167.2022.2130761","pmid":"https://pubmed.ncbi.nlm.nih.gov/36172806"},"language":"en","primary_location":{"id":"doi:10.1080/14737167.2022.2130761","doi":"https://doi.org/10.1080/14737167.2022.2130761","is_oa":false,"landing_page_url":"https://doi.org/10.1080/14737167.2022.2130761","pdf_url":null,"source":{"id":"https://openalex.org/S98544388","display_name":"Expert Review of Pharmacoeconomics & Outcomes Research","issn_l":"1473-7167","issn":["1473-7167","1744-8379"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Review of Pharmacoeconomics &amp; Outcomes Research","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4297965543"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5021893680","display_name":"Ghader Mohammadnezhad","orcid":"https://orcid.org/0000-0001-5300-349X","observed_orcids":["https://orcid.org/0000-0001-5300-349X","https://orcid.org/0009-0004-7055-9843"]},"institutions":[{"id":"https://openalex.org/I48379061","display_name":"Shahid Beheshti University","ror":"https://ror.org/0091vmj44","country_code":"IR","type":"education","lineage":["https://openalex.org/I48379061"]},{"id":"https://openalex.org/I58048189","display_name":"Shahid Beheshti University of Medical Sciences","ror":"https://ror.org/034m2b326","country_code":"IR","type":"education","lineage":["https://openalex.org/I58048189"]}],"countries":["IR"],"is_corresponding":false,"raw_author_name":"Ghader Mohammadnezhad","raw_affiliation_strings":["School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran"],"raw_orcid":"https://orcid.org/0000-0001-5300-349X","affiliations":[{"raw_affiliation_string":"School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran","institution_ids":["https://openalex.org/I48379061","https://openalex.org/I58048189"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043639831","display_name":"Behniya Azadmehr","orcid":"https://orcid.org/0000-0003-3944-7902","observed_orcids":["https://orcid.org/0000-0003-3944-7902"]},"institutions":[{"id":"https://openalex.org/I48379061","display_name":"Shahid Beheshti University","ror":"https://ror.org/0091vmj44","country_code":"IR","type":"education","lineage":["https://openalex.org/I48379061"]},{"id":"https://openalex.org/I58048189","display_name":"Shahid Beheshti University of Medical Sciences","ror":"https://ror.org/034m2b326","country_code":"IR","type":"education","lineage":["https://openalex.org/I58048189"]}],"countries":["IR"],"is_corresponding":false,"raw_author_name":"Behniya Azadmehr","raw_affiliation_strings":["School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran"],"raw_orcid":"https://orcid.org/0000-0003-3944-7902","affiliations":[{"raw_affiliation_string":"School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran","institution_ids":["https://openalex.org/I48379061","https://openalex.org/I58048189"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5057376555","display_name":"Nazila Yousefi","orcid":"https://orcid.org/0000-0001-8079-7424","observed_orcids":["https://orcid.org/0000-0001-8079-7424"]},"institutions":[{"id":"https://openalex.org/I48379061","display_name":"Shahid Beheshti University","ror":"https://ror.org/0091vmj44","country_code":"IR","type":"education","lineage":["https://openalex.org/I48379061"]},{"id":"https://openalex.org/I58048189","display_name":"Shahid Beheshti University of Medical Sciences","ror":"https://ror.org/034m2b326","country_code":"IR","type":"education","lineage":["https://openalex.org/I58048189"]}],"countries":["IR"],"is_corresponding":true,"raw_author_name":"Nazila Yousefi","raw_affiliation_strings":["Department of Pharmacoeconomics and Pharma Management, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran"],"raw_orcid":"https://orcid.org/0000-0001-8079-7424","affiliations":[{"raw_affiliation_string":"Department of Pharmacoeconomics and Pharma Management, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran","institution_ids":["https://openalex.org/I48379061","https://openalex.org/I58048189"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5057376555"],"corresponding_institution_ids":["https://openalex.org/I48379061","https://openalex.org/I58048189"],"apc_list":null,"apc_paid":null,"fwci":0.1188,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.11720698,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":93},"biblio":{"volume":"22","issue":"8","first_page":"1187","last_page":"1198"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10279","display_name":"Urinary Bladder and Prostate Research","score":0.9014000296592712,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10279","display_name":"Urinary Bladder and Prostate Research","score":0.9014000296592712,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.07989999651908875,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11232","display_name":"Urinary Tract Infections Management","score":0.0019000000320374966,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mirabegron","display_name":"mirabegron","score":0.996999979019165},{"id":"https://openalex.org/keywords/overactive-bladder","display_name":"overactive bladder","score":0.9950000047683716},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.902999997138977},{"id":"https://openalex.org/keywords/antimuscarinic-agents","display_name":"antimuscarinic agents","score":0.7960000038146973},{"id":"https://openalex.org/keywords/oxybutynin","display_name":"oxybutynin","score":0.9139999747276306},{"id":"https://openalex.org/keywords/fesoterodine","display_name":"fesoterodine","score":0.968999981880188},{"id":"https://openalex.org/keywords/tolterodine","display_name":"tolterodine","score":0.9959999918937683},{"id":"https://openalex.org/keywords/darifenacin","display_name":"darifenacin","score":0.9929999709129333},{"id":"https://openalex.org/keywords/trospium","display_name":"trospium","score":0.9980000257492065},{"id":"https://openalex.org/keywords/beta3-adrenergic-agonists","display_name":"beta3-adrenergic agonists","score":0.8650000095367432},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.9660000205039978},{"id":"https://openalex.org/keywords/incremental-cost-effectiveness-ratio","display_name":"incremental cost-effectiveness ratio","score":0.9340000152587891},{"id":"https://openalex.org/keywords/drug-therapy","display_name":"pharmacotherapy","score":0.6690000295639038}],"concepts":[{"id":"https://openalex.org/C2778164427","wikidata":"https://www.wikidata.org/wiki/Q3702534","display_name":"Mirabegron","level":4,"score":0.9956706166267395},{"id":"https://openalex.org/C2781020410","wikidata":"https://www.wikidata.org/wiki/Q424312","display_name":"Tolterodine","level":4,"score":0.9115134477615356},{"id":"https://openalex.org/C2778941218","wikidata":"https://www.wikidata.org/wiki/Q331231","display_name":"Overactive bladder","level":3,"score":0.8823491930961609},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8153150677680969},{"id":"https://openalex.org/C2779502394","wikidata":"https://www.wikidata.org/wiki/Q59575279","display_name":"Solifenacin","level":4,"score":0.6601424217224121},{"id":"https://openalex.org/C2777844464","wikidata":"https://www.wikidata.org/wiki/Q1060922","display_name":"Oxybutynin","level":4,"score":0.611468493938446},{"id":"https://openalex.org/C3019080777","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost effectiveness","level":2,"score":0.5919356346130371},{"id":"https://openalex.org/C500440147","wikidata":"https://www.wikidata.org/wiki/Q701216","display_name":"Pharmacotherapy","level":2,"score":0.5271750688552856},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.4720766544342041},{"id":"https://openalex.org/C2779343474","wikidata":"https://www.wikidata.org/wiki/Q3109175","display_name":"Context (archaeology)","level":2,"score":0.4612381160259247},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.33034059405326843},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.28779420256614685},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.16216158866882324},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.0},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000068737","descriptor_name":"Tolterodine Tartrate","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000083","descriptor_name":"Acetanilides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018727","descriptor_name":"Muscarinic Antagonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D053201","descriptor_name":"Urinary Bladder, Overactive","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1080/14737167.2022.2130761","doi":"https://doi.org/10.1080/14737167.2022.2130761","is_oa":false,"landing_page_url":"https://doi.org/10.1080/14737167.2022.2130761","pdf_url":null,"source":{"id":"https://openalex.org/S98544388","display_name":"Expert Review of Pharmacoeconomics & Outcomes Research","issn_l":"1473-7167","issn":["1473-7167","1744-8379"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-c","anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Review of Pharmacoeconomics &amp; Outcomes Research","raw_type":"journal-article"},{"id":"pmid:36172806","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/36172806","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert review of pharmacoeconomics & outcomes research","raw_type":"Systematic Review"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Systematic Review","id":"https://openalex.org/study-designs/systematic-review"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320323457","display_name":"Shahid Beheshti University of Medical Sciences","ror":"https://ror.org/034m2b326"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":33,"referenced_works":["https://openalex.org/W1583637726","https://openalex.org/W1787320721","https://openalex.org/W1987249698","https://openalex.org/W2009244027","https://openalex.org/W2020407610","https://openalex.org/W2020460752","https://openalex.org/W2033817897","https://openalex.org/W2064870203","https://openalex.org/W2066288167","https://openalex.org/W2074760879","https://openalex.org/W2082897746","https://openalex.org/W2083811107","https://openalex.org/W2096360296","https://openalex.org/W2109858998","https://openalex.org/W2130921523","https://openalex.org/W2136940899","https://openalex.org/W2143124566","https://openalex.org/W2143238509","https://openalex.org/W2300984620","https://openalex.org/W2416611247","https://openalex.org/W2466767377","https://openalex.org/W2773925409","https://openalex.org/W2782962160","https://openalex.org/W2805388448","https://openalex.org/W2809840734","https://openalex.org/W2887535210","https://openalex.org/W2901283882","https://openalex.org/W2902946292","https://openalex.org/W2909160308","https://openalex.org/W2963625979","https://openalex.org/W3089590920","https://openalex.org/W3094311767","https://openalex.org/W4226518246"],"related_works":["https://openalex.org/W2096360296","https://openalex.org/W2466767377","https://openalex.org/W4245130694","https://openalex.org/W2963625979","https://openalex.org/W2909160308","https://openalex.org/W2540498085","https://openalex.org/W2995488691","https://openalex.org/W2020407610","https://openalex.org/W2189805987","https://openalex.org/W4388500036"],"abstract_inverted_index":{"BACKGROUND:":[0],"Overactive":[1],"bladder":[2],"(OAB)":[3],"is":[4,28,151,174],"defined":[5],"as":[6],"urinary":[7,11],"urgency,":[8],"usually":[9],"with":[10,80,148,162],"frequency":[12],"and":[13,25,76,86,95,180],"nocturia.":[14],".":[15],"The":[16,82,121],"current":[17],"treatment":[18,48],"for":[19,167,171],"OAB":[20,172],"includes":[21],"conservative":[22],"management,":[23],"surgery,":[24],"pharmacotherapy.":[26],"Mirabegron":[27],"a":[29,110,184],"new":[30],"drug":[31],"acting":[32],"by":[33],"the":[34,42,47,66,90,101,133,136,153,160],"\u00df3-adrenoceptor":[35],"agonism.":[36],"This":[37],"study":[38,141],"aimed":[39],"to":[40,89,155,175],"review":[41],"cost-effectiveness":[43,97,122,137],"of":[44,49,123,132,138],"mirabegron":[45,107,116,124],"in":[46,57,65,104,127,146,159,183],"OAB.":[50],"AREAS":[51],"COVERED:":[52],"We":[53],"searched":[54],"published":[55],"articles":[56],"electronic":[58],"search":[59],"databases.":[60],"Ten":[61],"studies":[62,103,134,170],"were":[63,78,84],"included":[64],"qualitative":[67],"analysis.":[68],"Various":[69],"antimuscarinics,":[70],"including":[71],"oxybutynin,":[72],"fesoterodine,":[73],"tolterodine,":[74],"darifenacin,":[75],"trospium":[77],"compared":[79,87],"mirabegron.":[81,139],"results":[83],"evaluated":[85],"according":[88],"quality-adjusted":[91],"life-years":[92],"(QALY),":[93],"cost/year,":[94],"incremental":[96],"ratio":[98],"(ICER).":[99],"Of":[100],"ten":[102],"only":[105],"three,":[106],"was":[108,117,125],"not":[109],"cost-effective":[111],"strategy.":[112],"In":[113],"seven":[114],"cases,":[115],"cost-effective.":[118],"EXPERT":[119],"OPINION:":[120],"variable":[126],"different":[128,177],"regions;":[129],"however,":[130],"most":[131],"show":[135],"Our":[140,165],"illustrates":[142],"that":[143],"mirabegron's":[144],"ICER":[145],"comparison":[147],"its":[149],"comparators":[150],"below":[152],"willingness":[154],"pay":[156],"threshold":[157],"even":[158],"countries":[161],"low":[163],"GDP/Capita.":[164],"proposal":[166],"future":[168],"economic":[169],"pharmacotherapy":[173],"compare":[176],"doses,":[178],"formulations,":[179],"administration":[181],"forms":[182],"real-world":[185],"context.":[186]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4297965543","counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":1}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2022-10-01T00:00:00"}
